ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) updated its FY 2025 earnings guidance on Saturday. The company provided EPS guidance of 6.270-6.620 for the period, compared to the consensus EPS estimate of 6.340. The company issued revenue guidance of $768.0 million-$793.0 million, compared to the consensus revenue estimate of $769.6 million.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ANIP. Guggenheim reaffirmed a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. Finally, Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded down $0.31 during mid-day trading on Friday, reaching $65.50. 325,389 shares of the company's stock were exchanged, compared to its average volume of 311,463. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $77.00. The firm has a market capitalization of $1.42 billion, a PE ratio of 14.62 and a beta of 0.55. The business's fifty day simple moving average is $64.31 and its two-hundred day simple moving average is $61.65. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The business's revenue for the quarter was up 43.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.82 earnings per share. Analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Christopher Mutz sold 4,000 shares of the firm's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider now owns 107,317 shares of the company's stock, valued at approximately $6,487,312.65. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Ori Gutwerg sold 881 shares of ANI Pharmaceuticals stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the transaction, the senior vice president now owns 89,897 shares in the company, valued at approximately $5,400,112.79. This trade represents a 0.97% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,681 shares of company stock worth $346,854. Corporate insiders own 12.70% of the company's stock.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors have recently modified their holdings of ANIP. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock worth $736,000 after purchasing an additional 470 shares during the last quarter. Jane Street Group LLC bought a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $2,706,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after buying an additional 423 shares during the period. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.